ANOTHER BIG SONG FROM MY PAST... SHAKE IT OUT.... ELITE OR NOT LETS DO THIS--
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
THIS IS ONE OF THE BANDS I BROUGHT TO MTV WITH THE WARHOL SHOW 15 MINUTES-- I USED THIS SONG.
THESE GUYS TOO- I got them on US TV we interviewed them -- I Had a different take on the music back then very NME which was a magazine you got from England.-
With a world wide listening audience of....
269,105...... THIS IS
RADIO SAVANT-!
269,105...... THIS IS
Pfizer-backed Pyxis hits 52-week high to cross $200M market cap
AM I WRONG OR IT WAS ONLY A $S MIL INVEST. SHHHESH.
AM I WRONG OR IT WAS ONLY A $S MIL INVEST. SHHHESH.
Fluence Energy flies high after Goldman upgrades to Buy
FLNC Fluence Energy, Inc.
$19.01 +2.76(+16.98%)
FLNC Fluence Energy, Inc.
$19.01 +2.76(+16.98%)
I HATE TO CHASE HERE BUT.... I KNOW THESE GUYS HAD A CALL IN TODAY WITH SOME HOUSE.... SO I WAS WATCHING FOR ANY MID DAY SURGE.. AFTER THAT..--> HERE IT COMES!
GUMMY--> Microvast Holdings, Inc. (MVST)-@$1.15
NasdaqGS - NasdaqGS Real Time Price.
1.13+0.0550 (+5.09%)<---------------
As of 02:37PM EDT.
GUMMY--> Microvast Holdings, Inc. (MVST)-@$1.15
NasdaqGS - NasdaqGS Real Time Price.
1.13+0.0550 (+5.09%)<---------------
As of 02:37PM EDT.
HANGING OVER MVST'S HEAD-
DOE reviewing $200M grant to Microvast amid concerns, Bloomberg says 02/16 MVST The Department of Energy administration is reviewing $200M in funds it originally earmarked for Microvast (MVST) amid criticism about the company's ties to China, Ari Natter of Bloomberg reports. The Energy Department told concerned lawmakers the funding is undergoing "a thorough post-selection risk-based, due-diligence review," according to letters seen by Bloomberg. This is happening in consultation with the Department's Office of Intelligence and Counterintelligence among other agencies, Natter notes.
DOE reviewing $200M grant to Microvast amid concerns, Bloomberg says 02/16 MVST The Department of Energy administration is reviewing $200M in funds it originally earmarked for Microvast (MVST) amid criticism about the company's ties to China, Ari Natter of Bloomberg reports. The Energy Department told concerned lawmakers the funding is undergoing "a thorough post-selection risk-based, due-diligence review," according to letters seen by Bloomberg. This is happening in consultation with the Department's Office of Intelligence and Counterintelligence among other agencies, Natter notes.
IT WAS OPPENHEIMER I JUST CHECKED.
THERE IS A DANGER TO WRITING YOUR OWN OUTCOMES BUT WHAT IF THEY TELL OPPENHEIMER THAT THE ENERGY DEPT LOOKS LIKE IT'S SIGNING OFF ON THE CONTRACT...
AND TOMORROW UPGRADES?
THERE IS A DANGER TO WRITING YOUR OWN OUTCOMES BUT WHAT IF THEY TELL OPPENHEIMER THAT THE ENERGY DEPT LOOKS LIKE IT'S SIGNING OFF ON THE CONTRACT...
AND TOMORROW UPGRADES?
TOMORROW we should think about what Mr Mizuho said when he visited me last.
It was a strange visit I'll be honest.
He said to me.
Do you ever pleasure yourself and then go back to picking stocks? Do you find yourself looser, freer of thought and intent. Suddenly clear headed.
Erasca initiated with a Buy at Mizuho 16:21 ERAS Mizuho analyst Mara Goldstein initiated coverage of Erasca with a Buy rating and $9 price target. The analyst likes the company's "big pipeline" of targeted drug candidates that can participate in the multi-billion market of precision drugs. The shares have struggled this year as the dilution from the naporafenib deal is being absorbed but the combination of pipeline, addressable markets, data points over the next year, and Erasca's "long cash runway are compelling," the analyst tells investors in a research note.
It was a strange visit I'll be honest.
He said to me.
Do you ever pleasure yourself and then go back to picking stocks? Do you find yourself looser, freer of thought and intent. Suddenly clear headed.
Erasca initiated with a Buy at Mizuho 16:21 ERAS Mizuho analyst Mara Goldstein initiated coverage of Erasca with a Buy rating and $9 price target. The analyst likes the company's "big pipeline" of targeted drug candidates that can participate in the multi-billion market of precision drugs. The shares have struggled this year as the dilution from the naporafenib deal is being absorbed but the combination of pipeline, addressable markets, data points over the next year, and Erasca's "long cash runway are compelling," the analyst tells investors in a research note.